Schedule M

Indian Economy glossary

FlashcardsQuick reviseKey facts. One by one.Start →

Also called: Revised Schedule M, Good Manufacturing Practices schedule · Topic: Consumer Rights and Consumer Protection · NCERT: Beyond NCERT

Meaning

Schedule M is the part of the Drugs Rules, 1945 that sets out Good Manufacturing Practices (GMP) for making medicines in India. GMP means the quality standards for how medicines are made. Schedule M also sets the requirements for a factory's premises, plant and equipment. The Union Ministry of Health and Family Welfare (MoHFW) revised it through G.S.R. 922(E) on 28 December 2023 to bring it in line with WHO standards.

It matters because a patient cannot test a tablet or an injection before using it. The only protection is that the factory was made to follow strict rules. Schedule M puts the consumer's right to safety into practice for medicines, and it also shapes India's standing as a drug exporter.

Explanation

How it works

  • Where the rule comes from
  • The government approves medicines and sample-tests them to check that they meet quality standards. CDSCO does this under the Drugs and Cosmetics Act 1940.
  • The Drugs Rules, 1945 are framed under that Act. Schedule M is the part of those Rules that covers how medicines must be made.

  • Delegated legislation

  • This means the executive changes the rules using powers given to it by an Act. Parliament does not need to pass a new law each time.
  • Schedule M is changed through a G.S.R. notification (an official government order published in the Gazette). A draft is first released for public comments, and the final version is notified after that.

  • Who enforces it

  • Enforcement is shared between the CDSCO (the central regulator) and the State Drugs Controllers.
  • Licensing and much of the day-to-day enforcement sit with the States.

What the 2023 revision added

The old Schedule M mostly checked the factory building and its machines. The Revised Schedule M of 2023 also added:

  • a Pharmaceutical Quality System (PQS): a company-wide system that keeps quality steady across every batch;
  • Quality Risk Management (QRM): finding the steps where things are most likely to go wrong and controlling those steps first;
  • qualification and validation: proof, on record, that equipment and processes actually give the intended result.

The overall change is a move from "follow the checklist" to "prove your system controls risk".

Clean-area grades for sterile products

  • Sterile products are medicines that must be completely free of germs, such as injections and eye drops. For these, contamination directly affects patient safety.
  • Clean rooms are graded A to D. Grade A is the most critical zone. It is where exposed products, containers and sterilised components are handled.
  • Under WHO guidance, aseptic filling (filling in germ-free conditions) takes place in Grade A, with a Grade B or C room around it, depending on the operation.
  • WHO's microbial limit for Grade A is "No growth". It is checked when the room is at rest and also when it is working.
  • The benchmark text is WHO TRS No. 1044, Annex 2 (2022). It replaced TRS 961, Annex 6 (2011) and was prepared with the EU and PIC/S.

What makes compliance rise or fall

  • Firm size and cash
  • Small firms find cleanroom upgrades and monitoring systems costly.
  • That is why their compliance deadlines were extended more than once.

  • Inspection capacity

  • Weak state-level inspection capacity slows down consistent enforcement.

  • Self-monitoring

  • The manufacturer runs its own environmental monitoring.
  • So the rule is only as strong as the honesty of the firm's investigations and the checks that inspectors make on them.

In India

  • Ministry: MoHFW amends the Drugs Rules, including Schedule M.
  • Regulators:
  • CDSCO and the State Drugs Controllers enforce it.
  • In 2024 they carried out risk-based inspections of 400 premises, including MSMEs.
  • Firms are picked for inspection on criteria such as how many of their samples were declared Not of Standard Quality (NSQ, meaning a sample failed a quality test), complaints received, and how critical the product is.

  • Compliance timeline under the Revised Schedule M (2023):

Firm type Turnover Deadline
Large manufacturers Above ₹250 crore June 2024
Small and medium manufacturers ₹250 crore or less Extended, with conditions, to 31 December 2025 in February 2025; some PIB releases say 1 January 2026
  • Support scheme: RPTUAS (Revamped Pharmaceuticals Technology Upgradation Assistance Scheme) is run by the Department of Pharmaceuticals.
  • It covers units with turnover under ₹500 crore that are upgrading to the Revised Schedule M.
  • It reimburses 10–20% of eligible investment, depending on turnover, with a cap of ₹2 crore.
  • The money is paid only after a drug regulator certifies that the unit complies.
  • The outlay was ₹300.10 crore for 2024-25 to 2025-26.
  • By early 2026, 255 companies had sanctions worth ₹248.20 crore, but only ₹18.25 crore had been approved for payment, to 19 companies.

  • Latest step: a draft notification, G.S.R. 953(E) (28 October 2026), proposes aligning the Grade A microbial limits with WHO TRS 1044 Annex 2. Under it, any microbial growth in a Grade A area would trigger a root-cause investigation.

  • Consumer-protection link: Schedule M is part of the government's job of "setting quality and safety standards". It works alongside price ceilings on essential medicines, which the NPPA fixes under the Drug Price Control Order (DPCO).

Don't confuse with

  • Drugs and Cosmetics Act 1940: this is the parent Act. Schedule M sits inside the Drugs Rules, 1945, which are framed under that Act. The Act is a law made by Parliament; Schedule M is a rule changed by notification.
  • DPCO / NPPA: the DPCO and NPPA control the price of medicines. Schedule M controls how medicines are made.
  • Department of Pharmaceuticals: it sits under the Ministry of Chemicals & Fertilizers and runs RPTUAS. It does not amend Schedule M; MoHFW does.
  • BIS certification marks (ISI, Hallmark): these are product marks under the BIS Act 2016, mostly voluntary, and run by the Ministry of Consumer Affairs. Schedule M is a compulsory factory-level standard under health law, and it gives no consumer logo.

Prelims Hooks

  • Schedule M of the Drugs Rules, 1945 prescribes GMP and the requirements for premises, plant and equipment.
  • The Revised Schedule M was notified through G.S.R. 922(E), 28 December 2023. It added a Pharmaceutical Quality System, Quality Risk Management, and qualification and validation.
  • The benchmark for sterile products is WHO TRS No. 1044, Annex 2. It replaced TRS 961, Annex 6 (2011) and was co-developed with the EU and PIC/S.
  • WHO's Grade A microbial limit is "No growth". Grade A is where exposed products, containers and sterilised components are handled.
  • Turnover threshold: firms above ₹250 crore are large and had to comply by June 2024. Firms at ₹250 crore or less got extended deadlines.
  • Trap: the amending ministry is MoHFW, not the Department of Pharmaceuticals.

Mains Points

  • Export credibility vs MSME cost
  • WHO Prequalification inspectors check sterile sites against TRS 1044 Annex 2. Matching that text helps Indian injectables pass global inspections and protects India's place as "pharmacy of the world".
  • But RPTUAS pays only after compliance is certified and covers just 10–20% of the cost. So cash-poor small firms struggle to upgrade.
  • The fix is better financing, for example releasing the money in stages. A softer standard for small firms would mean a lower standard for the poorer patients who buy their products.

  • Rule vs enforcement

  • The 2023 revision moved from a checklist to a risk-based system.
  • But firms monitor themselves. Inspections are mostly triggered by past failures such as NSQ samples.
  • Without trained State inspectors who check raw records, a stricter rule can push firms to hide results instead of investigating them. PIC/S membership would require India to show that its inspections, not just its rules, meet the global standard.

  • Right fix for the right problem

  • The cough-syrup deaths came from diethylene glycol (an industrial chemical that is toxic when swallowed) in oral liquids.
  • Cleanroom norms for sterile products cannot stop a poisoned solvent from getting into a syrup. That needs testing of raw materials and solvents.
  • This is a strong example for GS-II answers on health regulation and consumer safety.

Recent developments

  • Nov 2026 – Draft rule for immediate licence suspension: The Union Health Ministry (MoHFW) published draft amendments to the Drugs Rules, 1945. If a drug is declared Not of Standard Quality (NSQ) on specified critical quality parameters, its manufacturing licence would be suspended immediately. Today a show-cause notice (a formal letter asking the firm to explain itself first) has to come before any suspension. The public has 30 days to comment, counted from the date copies of the Gazette of India are made available. This matters because Schedule M sets the quality rules, and this draft gives regulators a faster penalty when a drug fails them. Faulty drugs would no longer stay on the market while the paperwork is pending.
  • The trade-off in the draft (2026): The change moves from "hear first, act later" to "act first, hear later" for critical failures only. It weighs the firm's right to be heard (audi alteram partem) against patients' right to health under Article 21. Two limits to note: suspension only stops new production, so stock already in pharmacies still needs a separate recall; and the draft as reported sets no deadline for re-testing. This makes the draft a useful GS-II example of natural justice versus public interest in drug regulation.
  • 2024-25 – Scale of drug-quality failures: 3,104 NSQ cases and 245 spurious cases (fake drugs that deliberately misrepresent their identity or source) were reported in 2024-25. These numbers show why quick enforcement after GMP failures has become a priority.

Read more